it is possible that the SSRIs (i.e., fluvoxamine, fluoxetine, escitalopram) with sigma-1 receptor agonisms could be COVID-19 prophylactic drugs

[pattismith]

Mechanisms of action of fluvoxamine for COVID-19: a historical review | Molecular Psychiatry (nature.com)
07/01/2022

Collectively, fluvoxamine could likely be a prophylactic drug for early-stage SARS-CoV-2-infected patients [7, 22]. However, further multicenter randomized double-blind studies with a large sample size are needed.

Collectively, it is likely that the potent sigma-1 receptor agonist fluvoxamine might ameliorate ER stress-associated inflammatory events (i.e., cytokine storm) due to SARS-CoV-2 replication (Fig. 2) [7, 22].

Given the key role of the chaperone activity by sigma-1 receptor agonist in SARS-CoV-2 replication, it is possible that the SSRIs (i.e., fluvoxamine, fluoxetine, escitalopram) with sigma-1 receptor agonisms could be COVID-19 prophylactic drugs. Current data of fluoxetine and escitalopram for COVID-19 are from an observational study in France [21].

 

[SWAlexander]

somewhat related.
Reading for months almost every paper available, watching lectures on YouTube, I´m convinced now that LC and ME is fundamentally related to the malfunction of the endocrine system (metabolic energy) which affects organs and muscle. Either there is a shortage of specific hormone production, or hormones are lost in the bloodstream (high checked by micro clots), or receptors are blogged by viruses or bacteria.

 

[GlassCannonLife]

This is very interesting, I noticed it's in the I-recover protocol. Are there any "cleaner" sigma-1 receptor agonists?

Does donezepil not seem like a better option than SSRIs?